NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this randomized, double-blind, placebo-controlled, parallel group phase II
trial is to determine whether nicotinamide riboside (NIAGEN®, NR) can ameliorate persistent
peripheral neuropathy in cancer survivors who have completed chemotherapy with taxane or
platinum-complex compounds between 1 and 12 months earlier.